瑞替普酶治疗急性心肌梗死的有效性与安全性探讨

Analysis of the efficacy and safety of reteplase as thrombolytic therapy for acute myocardial infarction

目的:分析瑞替普酶治疗急性心肌梗死的有效性与安全性。方法:将北京市丰台区南苑医院2012年5月至2013年4月收治的60例急性心肌梗死患者分为观察组(n=30)和对照组(n=30),观察组采用瑞替普酶进行溶栓治疗,对照组采用尿激酶进行溶栓治疗。结果:观察组的冠状动脉再通率、再通时间、死亡率、并发症发生率均显著优于对照组(P<0.05),但两组患者的K-MB峰值时间和CK峰值时间差异无统计学意义(P>0.05)。结论:瑞替普酶治疗急性心肌梗死疗效确切,安全性好,值得临床推广应用。

Objective： To analyze the efficacy and safety of reteplase as thrombolytic therapy for acute myocardial infarction. Methods： 60 patients with acute myocardial infarction in Nanyuan Hospital of Fengtai District from May 2011 to April 2013 were divided into observation group（ n = 30）and control group（ n = 30）. Observation group was given reteplase and control group was given urokinase as thrombolytic therapy. Results： The coronary artery recanalization rate,recanalization time,death rate,and complication rate in observation group were significantly better than those in control group（ P 0. 05）. However,there were no significant differences in peak times of K-MB and CK between two groups（ P 0. 05）. Conclusion： It is safe and efficient to use reteplase as thrombolytic therapy for acute myocardial infarction. It is worthy to be popularized.